Jubilant Biosys, a Bengaluru-based subsidiary of Jubilant Life Sciences, and Orion Corporation the largest pharmaceutical company in Finland, today announced a path breaking drug discovery collaboration to discover small molecule inhibitors in neuroscience therapeutic area. The research deal is aimed at developing drug that can benefit large population of people with unmet needs in the pain management area.

As per the terms of agreement, Jubilant’s extensive experience in drug discovery and pre-clinical development will be utilised by Orion to address pain management needs of Central Nervous System (CNS). Jubilant will offer integrated drug discovery services across early discovery, synthetic and medicinal chemistry including scale up and pre-clinical services. The research for the project, which has been initiated, will be undertaken primarily at state-of-the-art R&D labs of Jubilant Biosys (India) and some parts at Jubilant Discovery Center, USA.

According to Dr. Subir Kumar Basak, president, Jubilant Biosys Ltd., “over the past few years, we have been strengthening our therapeutic area focused discovery platform, and this partnership serves as a validation of our efforts. We are confident of offering successful results to Orion at various stages of research.”

Dr. Jukka Sallinen, Head, CNS Research of Orion Pharma R&D, said, “Jubilant Biosys is widely recognised for its expertise in offering integrated services in Drug Discovery and Development Solutions and for its prodigious capabilities in Pain and Inflammation. With established ability to develop successful drugs, we consider Jubilant as our ideal partner to take forward our strategic business plans with optimum time-to-market and accuracy.”

Jubilant will receive research funding from Orion for delivering Hit, Lead Generation and Optimisation milestone, according to a pre-defined research plan.  Under the royalty based alliance, Orion will provide royalty to Jubilant and will retain ownership of the compounds developed under the collaboration with exclusive worldwide rights.